Affiliation:
1. Open Health Evidence & Access, Bethesda, MD 20814, USA
2. Merck & Co., Inc., Kenilworth, NJ 07033, USA
Abstract
Aim: To evaluate treatment patterns, healthcare resource use (HCRU) and all-cause healthcare costs among patients with cervical or endometrial cancer newly initiating systemic therapy. Methods: We identified patients with cervical or endometrial cancer newly initiating systemic therapy – a claims-based proxy for advanced disease – between 2014 and 2019, described them by line of therapy (LOT), and summarized the per patient per month (PPPM) HCRU and healthcare costs per LOT. Results: Among 1229 patients with cervical cancer and 2659 patients with endometrial cancer, LOT1 therapies included systemic only (cervical, 50.1%; endometrial, 83.2%) and systemic with radiation therapy (cervical, 49.9%; endometrial, 16.8%). Mean PPPM total costs were: LOT1 (cervical, US$15,892; endometrial, US$11,363), LOT2 (US$20,193; US$14,019) and LOT3+ (US$16,576; US$14,645). Conclusions: Overall, patients received guideline-concordant care and experienced significant economic burden, which increased with LOT.
Subject
Cancer Research,Oncology,General Medicine
Reference22 articles.
1. American Cancer Society. Cancer facts & figures 2019 (2019). www.cancer.org/cancer/cervical-cancer/about/key-statistics.html
2. American Cancer Society.Key Statistics for Cervical Cancer (2019). www.cancer.org/cancer/cervical-cancer/about/key-statistics.html
3. Demographic and insurance-based disparities in diagnosis of stage IV cervical cancer: A population-based analysis using NCDB.
4. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献